SCHEMBL4339912

SCHEMBL4339912

NOC(=O)OC12CC3CC(CC(C3)C1)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.42
CYP19A1 P11511 4/20 0.40
NAAA Q02083 1/20 0.38
CA2 P00918 1/20 0.38
CYP17A1 P05093 3/20 0.36
EPHX2 P34913 2/20 0.36
THRB P10828 1/20 0.36
CYP2C9 P11712 1/20 0.36
EPHX1 P07099 3/20 0.35
TSHR P16473 3/20 0.35
ALDH1A1 P00352 3/20 0.35
SLC22A2 O15244 1/20 0.33
SLC22A1 O15245 1/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
LMNA P02545 1/20 0.33
NFKB1 P19838 1/20 0.33
STAT6 P42226 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL865315 0.86 NPSR1 (0.48) NPSR1CYP19A1NAAACA2CYP17A1
SCHEMBL1439502 0.78 NPSR1 (0.42) NPSR1CYP19A1NAAACA2CYP17A1
SCHEMBL3125283 0.78 NPSR1 (0.47) NPSR1CYP19A1NAAACYP17A1EPHX2
SCHEMBL18394764 0.78 NPSR1 (0.42) NPSR1CYP19A1NAAACA2CYP17A1
SCHEMBL113024 0.77 CYP19A1 (0.42) NPSR1CYP19A1NAAACA2CYP17A1
Ammonia Solution, Strong SCHEMBL28325233 0.77 NPSR1 (0.45) NPSR1CYP19A1NAAACYP17A1EPHX2
SCHEMBL27736443 0.77 CYP19A1 (0.44) NPSR1CYP19A1NAAACA2CYP17A1
Hydrochloric Acid SCHEMBL27804949 0.76 EPHX1 (0.41) NPSR1CYP19A1NAAACA2CYP17A1
SCHEMBL7183801 0.75 NPSR1 (0.39) NPSR1CYP19A1NAAACA2CYP17A1
SCHEMBL4222114 0.75 CYP19A1 (0.43) NPSR1CYP19A1NAAACA2CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090246233-A1 Treatment of Gastroparesis and Nonulcer Dyspepsia With GABAB Agonists AGI THERAPEUTICS RESEARCH LTD. 2009-10-01 US disclosed
EP-1675581-A1 TREATMENT OF GASTROPARESIS AND NONULCER DYSPEPSIA WITH GABA-b AGONISTS AGI THERAPEUTICS RESEARCH LIMITED (IE) 2006-07-05 EP disclosed
US-20050090554-A1 Administering baclofen, or a salt thereof, to relieve at least one symptom of gastroparesis other than vomiting AGI THERAPEUTICS LTD. (IE) 2005-04-28 US disclosed
WO-2005025559-A1 TREATMENT OF GASTROPARESIS AND NONULCER DYSPEPSIA WITH GABAB AGONISTS AGI THERAPEUTICS LTD. (US) 2005-03-24 WO disclosed